BMCM
ARLZ

Bryn Mawr Capital Management’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Bryn Mawr Capital Management’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-113,752
Closed -$260K – 95
2017
Q4 		$260K Hold
113,752
– – 0.34% 48
2017
Q3 		$260K Buy
113,752
+17,147
+18% +$22.9K 0.27% 57
2017
Q2 		$130K Sell
96,605
-10,887
-10% -$15.7K 0.15% 67
2017
Q1 		$230K Hold
107,492
– – 0.24% 65
2016
Q4 		$474K Buy
+107,492
New +$510K 0.48% 37

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $4.03B AUM 35.05% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
SM
Salzhauer Michael $292M AUM 30% 1-Year Est. Return

Bryn Mawr Capital Management's ARLZ Position: Q1 2018 in Review

Bryn Mawr Capital Management sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q1 2018, closing a stake of 113,752 shares — an estimated $260K sold.

Bryn Mawr Capital Management first reported a position in ARLZ in Q4 2016 and held it in 5 quarters. The position peaked at $474K in Q4 2016. 56 funds tracked by Wall St. Rank hold ARLZ as of Q1 2018.

  • Bryn Mawr Capital Management reported no remaining Aralez Pharmaceuticals Inc. position as of Q1 2018 after selling out during the quarter.
  • Bryn Mawr Capital Management sold 113,752 Aralez Pharmaceuticals Inc. shares in Q1 2018, an estimated $260K.
  • Bryn Mawr Capital Management first reported a position in Aralez Pharmaceuticals Inc. in Q4 2016 and held it in 5 quarters.
  • Bryn Mawr Capital Management's Aralez Pharmaceuticals Inc. position peaked at $474K in Q4 2016.
  • 56 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q1 2018.

Based on Bryn Mawr Capital Management's 13F filing for Q1 2018, filed 11 May 2018.